Glenmark gets USFDA’s tentaive nod for Dapagliflozin drug

Our Bureau Mumbai | Updated on March 23, 2020

Glenmark Pharmaceuticals Inc., USA , a part of Glenmark Pharmaceuticals has been granted tentative approval by the United States Food & Drug Administration (USFDA) for Dapagliflozin Tablets, 5 mg and 10 mg. These tablets are generic versions of Farxiga1 tablets, used in the treatment of diabetes, made by AstraZeneca AB.

According to IQVIATM sales data for the 12 month period ending January 2020, the Farxiga Tablets, 5 mg and 10 mg market has annual sales of $1.8 billion. At 10.35 am, Glenmark stocks were trading at ₹197 or 6.41 per cent down.

Published on March 23, 2020

Follow us on Telegram, Facebook, Twitter, Instagram, YouTube and Linkedin. You can also download our Android App or IOS App.

This article is closed for comments.
Please Email the Editor